CN1297448A - 帕罗西汀抗坏血酸盐 - Google Patents

帕罗西汀抗坏血酸盐 Download PDF

Info

Publication number
CN1297448A
CN1297448A CN99805160A CN99805160A CN1297448A CN 1297448 A CN1297448 A CN 1297448A CN 99805160 A CN99805160 A CN 99805160A CN 99805160 A CN99805160 A CN 99805160A CN 1297448 A CN1297448 A CN 1297448A
Authority
CN
China
Prior art keywords
paroxetine
compound
ascorbate
solution
paroxetine ascorbate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN99805160A
Other languages
English (en)
Chinese (zh)
Inventor
M·乌尔屈哈特
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Ltd
Original Assignee
SmithKline Beecham Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SmithKline Beecham Ltd filed Critical SmithKline Beecham Ltd
Publication of CN1297448A publication Critical patent/CN1297448A/zh
Pending legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4525Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
CN99805160A 1998-04-25 1999-04-23 帕罗西汀抗坏血酸盐 Pending CN1297448A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB9808896.6 1998-04-25
GBGB9808896.6A GB9808896D0 (en) 1998-04-25 1998-04-25 Novel compound

Publications (1)

Publication Number Publication Date
CN1297448A true CN1297448A (zh) 2001-05-30

Family

ID=10831008

Family Applications (1)

Application Number Title Priority Date Filing Date
CN99805160A Pending CN1297448A (zh) 1998-04-25 1999-04-23 帕罗西汀抗坏血酸盐

Country Status (20)

Country Link
EP (1) EP1089995A1 (no)
JP (1) JP2002513019A (no)
KR (1) KR20010042977A (no)
CN (1) CN1297448A (no)
AP (1) AP2000001963A0 (no)
AU (1) AU3618499A (no)
BG (1) BG104940A (no)
BR (1) BR9909868A (no)
CA (1) CA2330055A1 (no)
EA (1) EA200001104A1 (no)
GB (1) GB9808896D0 (no)
HU (1) HUP0102116A3 (no)
ID (2) ID26654A (no)
IL (1) IL139081A0 (no)
NO (1) NO20005352D0 (no)
PL (1) PL343677A1 (no)
SK (1) SK15912000A3 (no)
TR (1) TR200003084T2 (no)
WO (1) WO1999055698A1 (no)
ZA (1) ZA200005912B (no)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110607554A (zh) * 2018-10-30 2019-12-24 中国科学院化学研究所 一种制备药物或药物中间体单晶或无定型物的方法

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0003232D0 (en) * 2000-02-11 2000-04-05 Smithkline Beecham Plc Novel composition
IL159280A0 (en) * 2001-06-14 2004-06-01 Teva Pharma A process for preparing paroxetine hcl which limits formation of pink colored compounds
ES2412306T3 (es) 2002-01-09 2013-07-11 Emisphere Technologies, Inc. Polimorfos de 4-((4-cloro-2-hidroxibenzoil)amino)butanoato de sodio

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1422263A (en) * 1973-01-30 1976-01-21 Ferrosan As 4-phenyl-piperidine compounds
DE3688827T2 (de) * 1985-10-25 1994-03-31 Beecham Group Plc Piperidinderivat, seine Herstellung und seine Verwendung als Arzneimittel.
US5276042A (en) * 1993-04-16 1994-01-04 Crenshaw Roger T Treatment of premature ejaculation
ES2117557B1 (es) * 1996-02-29 1999-07-01 Ferrer Int Nuevo procedimiento de obtencion de (-)-trans -n-p-fluorobenzoilmetil-4-(p-fluorofenil)-3- ((3,4-(metilendioxi)fenoxi ) metil)-piperidina.

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110607554A (zh) * 2018-10-30 2019-12-24 中国科学院化学研究所 一种制备药物或药物中间体单晶或无定型物的方法
CN110607553A (zh) * 2018-10-30 2019-12-24 中国科学院化学研究所 一种制备粒径可调的药物或药物中间体单晶或无定型物的方法
CN110607553B (zh) * 2018-10-30 2024-03-22 中国科学院化学研究所 一种制备粒径可调的药物或药物中间体单晶或无定型物的方法
CN110607554B (zh) * 2018-10-30 2024-03-22 中国科学院化学研究所 一种制备药物或药物中间体单晶或无定型物的方法

Also Published As

Publication number Publication date
WO1999055698A1 (en) 1999-11-04
AU3618499A (en) 1999-11-16
HUP0102116A3 (en) 2002-12-28
IL139081A0 (en) 2001-11-25
JP2002513019A (ja) 2002-05-08
BG104940A (bg) 2001-09-28
EA200001104A1 (ru) 2001-04-23
ID26083A (id) 2000-11-23
SK15912000A3 (sk) 2001-04-09
ZA200005912B (en) 2001-12-19
HUP0102116A2 (hu) 2002-05-29
EP1089995A1 (en) 2001-04-11
PL343677A1 (en) 2001-08-27
NO20005352L (no) 2000-10-24
NO20005352D0 (no) 2000-10-24
GB9808896D0 (en) 1998-06-24
TR200003084T2 (tr) 2001-02-21
CA2330055A1 (en) 1999-11-04
BR9909868A (pt) 2000-12-19
ID26654A (id) 2001-01-25
KR20010042977A (ko) 2001-05-25
AP2000001963A0 (en) 2000-12-31

Similar Documents

Publication Publication Date Title
KR100514264B1 (ko) 피페리디노알칸올-충혈완화제 조합용 제약 조성물
AU2011201520B2 (en) Capsule Formulation Of Pirfenidone And Pharmaceutically Acceptable Excipients
CA1327011C (en) Pharmaceutical compositions for piperidino alkanol-ibuprofen combination
US20040242506A1 (en) Paroxetine glycyrrhizinate
WO1999052931A1 (fr) Dispersion solide contenant un derive d'acide sialique
CN1297448A (zh) 帕罗西汀抗坏血酸盐
EP0310999B1 (en) Pharmaceutical composition for piperidinoalkanol derivatives
SK286040B6 (sk) Farmaceutická kompozícia obsahujúca 1-(2-naft-2-yletyl)-4-(3- trifluórmetylfenyl)-1,2,3,6-tetrahydropyridín hydrochlorid a donepezil alebo takrín
DE60220953T2 (de) Pharmazeutische zusammensetzungen enthaltend eine antihistaminische abschwellende arzneistoffkombination und ein verfahren zur herstellung davon
AU2013201986B2 (en) Capsule Formulation Of Pirfenidone And Pharmaceutically Acceptable Excipients
JPS62190126A (ja) ジフルニザ−ルとトロメタミンの混合組成物
WO1999055699A1 (en) Paroxetine 10-camphorsulfonate for treatment of cns disorders
MXPA99011699A (en) Pharmaceutical composition for combination of piperidinoalkanol-decongestant
MXPA00010439A (en) Paroxetine ascorbate
MXPA00010435A (en) Paroxetine 10-camphorsulfonate for treatment of cns disorders

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication